Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-07-31

FDA Approved: KALYDECO — Supplemental Application (Vertex Pharmaceuticals Incorporated)

View source ↗

Summary

The FDA approved Vertex's supplemental application for KALYDECO (ivacaftor), authorizing changes to the product labeling through a supplemental approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Kalydeco (ivacaftor)

Snippet

SUPPL AP for KALYDECO (IVACAFTOR)